Visit https://www.peervoice.com/CGZ860 to view the entire programme with slides. After completing “Bruno Sangro, MD, PhD - A New Era in the Management of Advanced HCC: Sequencing Therapies for the Second-Line and Beyond”, participants will be able to: Identify key decision points in the sequencing of therapies in advanced hepatocellular carcinoma (HCC) and patient assessments to guide transitions from first- to second-line treatment; Evaluate available data to guide the appropriate choice and sequencing of therapies in the second-line setting for advanced HCC and their use following first-line treatment strategies; and Use an informed approach when sequencing therapies for individual patients with advanced HCC based on available data, pharmacologic characteristics of approved therapies, and patient-specific factors.